Clinical trials: Phase 2, completed
Squamous Cell Carcinoma
Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract
Patients will be randomised after surgery, provided surgery is macroscopically adequate, that there is a flap of tissue protecting the vascular axis and that wound healing allows reirradiation to begin less than 8 weeks after…
- Trial name
- JANORL2 (NCT01211938)
- Testing
- single-fraction radiotherapy with concomitant 5FU and Hydrea, hyperfractionated radiotherapy with concomitant Cetuximab
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Non Small Cell Lung Cancer
Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes
Lung cancer is the worldwide leading cause of cancer death. In France, with 28,000 new cases per year, lung cancer is the 4th in terms of incidence but remains the leading cause of cancer death.
- Trial name
- CSET 1437 (NCT01159288)
- Testing
- Dex2
- Where
- France
- Volunteers
- 41 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Human Papillomavirus Infection
Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts
This is a blinded study to assess safety, tolerability, and efficacy of ABI-2280 vaginal inserts in participants diagnosed with persistent cervical hrHPV infection.
- Trial name
- NCT06491446
- Testing
- ABI-2280
- Where
- 24 sites in Australia, Kenya and 2 more
- Volunteers
- 141 people
- Sponsor
- Antiva Biosciences
Pneumococcal Infectious Disease
Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
A phase II clinical trial of a 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older.
- Trial name
- NCT06678620
- Testing
- Reinovax PCV24 formulation 1, Reinovax PCV24 formulation 2, Reinovax PCV24 formulation 3
- Where
- 2 sites in China
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
Obesity, Overweight
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
- Trial name
- EVOLVE-2 (NCT07281937)
- Testing
- VRB-101
- Where
- 22 sites in United States
- Volunteers
- 206 people
- Sponsor
- Verdiva Bio Dev Limited
Melanoma
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.
- Trial name
- NCT04370704
- Testing
- INCAGN02385, INCAGN02390, INCMGA00012.
- Where
- 17 sites in United States, Australia
- Volunteers
- 61 people
- Sponsor
- Incyte Corporation
Lung Cancer, Metastasis
Radiofrequency Ablation of Lung Tumors
Radiofrequency ablation has achieved impressive results in the treatment of unresectable primary and metastatic liver cancer. Animal studies have demonstrated that radiofrequency can fully ablate lung tumors in animal models.
- Trial name
- NCT00180856
- Testing
- Radiofrequency ablation
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Anus Neoplasms, HIV Infections
Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men
The purpose of this study is to assess if argon plasma coagulation (APC) is a safe and well tolerated treatment method for anal intraepithelial neoplasia (AIN) grade 2/3 in HIV-positive men having sex with men (MSM).
- Trial name
- NCT00428285
- Testing
- Argon Plasma Coagulation
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
SCI - Spinal Cord Injury, Neuropathic Pain
Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI
The main purposes of this study are to (1) measure the effect of CBD/CBD-A on pain symptoms, pain intensity, pain unpleasantness, and skin sensitivity to hot and cold temperatures; and (2) measure the effect of CBD on brain…
- Trial name
- NCT05630235
- Testing
- CBD/CBD-A
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
Adenosquamous Carcinoma of the Pancreas
Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
Background: Pancreatic cancer is one of the most lethal types of cancer. American Society for Clinical Pathology (ASCP) is a highly aggressive type of pancreatic cancer. It is very rare.
- Trial name
- NCT04896073
- Testing
- Minnelide, ECG, CT/MRI
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Infection, Human Immunodeficiency Virus
Phase Ib/IIa Clinical Study of ACC017 Tablets
ACC017 is an integrase inhibitor that will be evaluated for the treatment of HIV infection. This phase Ib/IIa, randomized, double-blind, parallel, dose ranging, placebo-controlled 'proof of concept' study is designed to evaluate…
- Trial name
- NCT06719310
- Testing
- ACC017+FTC/TAF
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Single-ventricle, Infant Conditions
PK/PD of Digoxin in Infants With SVHD
The primary participant will be an infant with single ventricle heart disease. This is a research study to learn more about how the medication digoxin, which is routinely prescribed to infants and children with heart disease in…
- Conditions
- Single-ventricle, Infant Conditions, Infant, Newborn, Diseases, Infant, Premature, Diseases
- Trial name
- Digoxin R01 (NCT06613477)
- Testing
- PK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Prostate Cancer (Post Prostatectomy)
Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy
The goal of this clinical trial is to compare 64Cu-SAR-bisPSMA PET/CT and 68Ga PSMA-11 PET/CT in men with biochemical failure following radical prostatectomy.
- Trial name
- Co-PSMA (NCT06907641)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- Australia
- Volunteers
- 50 people
- Sponsor
- St Vincent's Hospital, Sydney
Non-Small Cell Lung Cancer
Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer
The combination of immune checkpoint inhibitors (ICI) and local ablative radiotherapy has been demonstrated to be able to increase the survival of patients with metastatic driven-genes negative non-small cell lung cancer.
- Trial name
- NCT05348668
- Testing
- Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Anhui Provincial Hospital
Non-small Cell Lung Cancer, Consolidation Immunotherapy
Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients
The current standard of care for locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiation and consolidation immunotherapy.
- Conditions
- Non-small Cell Lung Cancer, Consolidation Immunotherapy, Radiotherapy or Sequential Chemoradiation
- Trial name
- NCT05758116
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Peking University Cancer Hospital & Institute
Ketamine, Anesthesia
Use of S+Ketamine During Target-Controlled Intravenous Anaesthesia After Abdominal Hysterectomy
The investigators want to investigate the effect of low dose S+ ketamine compared to placebo on cumulative morphine consumption at 24 hours in 90 women undergoing open abdominal hysterectomy with remifentanil-propofol target…
- Conditions
- Ketamine, Anesthesia, Morphine, Hysterectomy
- Trial name
- NCT03231683
- Testing
- Esketamine, Saline, Remifentanil
- Where
- Singapore
- Volunteers
- 90 people
- Sponsor
- KK Women's and Children's Hospital
Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma
Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
Immunotherapy targeting the PD-1/PD-L1 pathway had previously been shown to be efficacious in the treatment of patients with metastatic head and neck squamous cell carcinomas.
- Trial name
- NCT03283605
- Testing
- SBRT, Durvalumab, Tremelimumab
- Where
- 3 sites in Canada
- Volunteers
- 33 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Non-small Cell Lung Cancer Metastatic
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
the study conducted to evaluate the efficacy and safety of high-dose furmonertinib (160 mg qd) combined with bevacizumab and pemetrexed intrathecal chemotherapy in NSCLC patients with EGFR mutations and meningeal metastases.
- Trial name
- NCT06812871
- Testing
- furmonertinib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
Post-operative Nausea and Vomiting
Prevention of Post-Operative Nausea and Vomiting With Propofol Infusion
The purpose of this study is to clarify whether or not a low-dose propofol infusion can effectively prevent postoperative nausea and vomiting (PONV) in patients who have a documented history of PONV and/or motion sickness.
- Trial name
- PONV (NCT05759481)
- Testing
- Hybrid anesthesia (propofol + sevoflurane), Propofol only TIVA
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Milton S. Hershey Medical Center
Idiopathic Pulmonary Fibrosis
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05671835
- Testing
- TTI-101
- Where
- 28 sites in United States
- Volunteers
- 100 people
- Sponsor
- Tvardi Therapeutics, Incorporated